TOP > 外国特許検索 > ANTITUMOR AGENT

ANTITUMOR AGENT

外国特許コード F160008856
整理番号 (S2015-0491-N0)
掲載日 2016年9月23日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP053960
国際公開番号 WO 2016129633
国際出願日 平成28年2月10日(2016.2.10)
国際公開日 平成28年8月18日(2016.8.18)
優先権データ
  • 特願2015-024713 (2015.2.10) JP
発明の名称 (英語) ANTITUMOR AGENT
発明の概要(英語) The present invention provides a composition and method for treatment or prevention in a subject having a tumor (e.g., a brain tumor, breast cancer, colon cancer, prostate cancer, liver cancer, lung cancer, leukemia, lymphoma, or the like) in which the TUG1 gene is expressed at a high level relative to normal tissue, the composition including as an active ingredient a nucleic acid for suppressing high-level expression of the TUG1 gene in tumor stem cells.
特許請求の範囲(英語) [claim1]
1. It includes the nuclear acid which controls the high revelation of the TUG1 gene in the tumor trunk cell as the active ingredient the TUG1 gene in comparison with normality organization high the composition in order it remedies or to prevent the suffering *** body which possesses the tumor which is revealed.
[claim2]
2. The aforementioned nuclear acid, confronts the copying body RNA of the TUG1 gene, siRNA and that precusor RNA, it is anti sense RNA, or the decoration RNA or anti sense DNA, in claim 1 the composition of statement.
[claim3]
3. The aforementioned nuclear acid, respectively, the nucleotide number 1044-1062, the 1044-1062 or the 1044-1062, and/or, the nucleotide number 2997-5181, designates the territory of the 2941-5111 or the 2941-5125 as the target SEQ ID NO 1 of copying body RNA of the TUG1 gene, at the time of 2 or 3 base arranging, in claim 1 or 2 the composition of statement.
[claim4]
4. The aforementioned nuclear acid, siRNA and that precusor RNA which include with the anti sense chain which consists of respectively the base arrangement of the complimentary SEQ ID NO 12-19 of the sense chain and the said sense chain which consist of the base arrangement of the SEQ ID NO 4-11 or either of the decoration RNA is or more the combination of one or two, either of the claim 1-3 in 1 sections the composition of statement.
[claim5]
5. The aforementioned decoration RNA, includes or more the decoration nucleotide or deoxyribonucleotide of one or two, either of the claim 2-4 in 1 sections the composition of statement.
[claim6]
6. The decoration RNA including the aforementioned deoxyribonucleotide, siRNA which includes with the anti sense chain which consists of the base arrangement of the SEQ ID NO 28-35 which includes respectively the complimentary arrangement of the sense chain and the said sense chain which consist of the base arrangement of the SEQ ID NO 20-27, or, is the anti sense RNA/DNA chimera which consists of the base arrangement of the SEQ ID NO 28-35, in claim 5 the composition of statement.
[claim7]
7. It is the LNA decoration anti sense RNA which at least includes two where the decoration RNA which includes the aforementioned decoration nucleotide, in each end, 2 ' - O, 4 ' - has C methylene bridge and is locked LNA decoration nucleotides, in claim 5 the composition of statement.
[claim8]
8. The aforementioned decoration RNA, the SEQ ID NO 36-38, is the LNA decoration anti sense RNA which consists of each base arrangement of the 51-53, the claim 2-3, either of the 5-7 in 1 sections the composition of statement.
[claim9]
9. The aforementioned nuclear acid, confronts the copying body RNA of the TUG1 gene, DNA or the anti sense DNA which siRNA, that precusor RNA or anti sense RNA the cord/code is done, it is the vector which is included, either of the claim 1-6 in 1 sections the composition of statement.
[claim10]
10. The aforementioned tumor, the encephaloma, the breast cancer, the colon cancer, the prostate cancer, the liver cancer and the lung cancer, is selected from the group which consists of the leukemia and the lymph swelling, either of the claim 1-9 in 1 sections the composition of statement.
[claim11]
11. Either of the claim 1-10 the fact that the composition of statement is prescribed to the suffering *** body in 1 sections is included, the TUG1 gene in comparison with normality organization high method in order to remedy the suffering *** body which possesses the tumor which is revealed.
[claim12]
12. The aforementioned tumor, the encephaloma, the breast cancer, the colon cancer, the prostate cancer, the liver cancer and the lung cancer, is selected from the group which consists of the leukemia and the lymph swelling, in claim 11 method of statement.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NAGOYA CITY UNIVERSITY
  • 発明者(英語)
  • KONDO YUTAKA
  • KATSUSHIMA KEISUKE
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close